FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3024960011> ?p ?o ?g. }

• W3024960011 endingPage "137" @default.
• W3024960011 startingPage "123" @default.
• W3024960011 abstract "CRADLE was a 36-month multicenter study in pediatric (≥1 to <18 years) kidney transplant recipients randomized at 4 to 6 weeks posttransplant to receive everolimus + reduced-exposure tacrolimus (EVR + rTAC; n = 52) with corticosteroid withdrawal at 6-month posttransplant or continue mycophenolate mofetil + standard-exposure TAC (MMF + sTAC; n = 54) with corticosteroids. The incidence of composite efficacy failure (biopsy-proven acute rejection [BPAR], graft loss, or death) at month 36 was 9.8% vs 9.6% (difference: 0.2%; 80% confidence interval: –7.3 to 7.7) for EVR + rTAC and MMF + sTAC, respectively, which was driven by BPARs. Graft loss was low (2.1% vs 3.8%) with no deaths. Mean estimated glomerular filtration rate at month 36 was comparable between groups (68.1 vs 67.3 mL/min/1.73 m2). Mean changes (z-score) in height (0.72 vs 0.39; P = .158) and weight (0.61 vs 0.82; P = .453) from randomization to month 36 were comparable, whereas growth in prepubertal patients on EVR + rTAC was better (P = .050) vs MMF + sTAC. The overall incidence of adverse events (AEs) and serious AEs was comparable between groups. Rejection was the leading AE for study drug discontinuation in the EVR + rTAC group. In conclusion, though AE-related study drug discontinuation was higher, an EVR + rTAC regimen represents an alternative treatment option that enables withdrawal of steroids as well as reduction of CNIs for pediatric kidney transplant recipients.ClinicalTrials.gov: NCT01544491. CRADLE was a 36-month multicenter study in pediatric (≥1 to <18 years) kidney transplant recipients randomized at 4 to 6 weeks posttransplant to receive everolimus + reduced-exposure tacrolimus (EVR + rTAC; n = 52) with corticosteroid withdrawal at 6-month posttransplant or continue mycophenolate mofetil + standard-exposure TAC (MMF + sTAC; n = 54) with corticosteroids. The incidence of composite efficacy failure (biopsy-proven acute rejection [BPAR], graft loss, or death) at month 36 was 9.8% vs 9.6% (difference: 0.2%; 80% confidence interval: –7.3 to 7.7) for EVR + rTAC and MMF + sTAC, respectively, which was driven by BPARs. Graft loss was low (2.1% vs 3.8%) with no deaths. Mean estimated glomerular filtration rate at month 36 was comparable between groups (68.1 vs 67.3 mL/min/1.73 m2). Mean changes (z-score) in height (0.72 vs 0.39; P = .158) and weight (0.61 vs 0.82; P = .453) from randomization to month 36 were comparable, whereas growth in prepubertal patients on EVR + rTAC was better (P = .050) vs MMF + sTAC. The overall incidence of adverse events (AEs) and serious AEs was comparable between groups. Rejection was the leading AE for study drug discontinuation in the EVR + rTAC group. In conclusion, though AE-related study drug discontinuation was higher, an EVR + rTAC regimen represents an alternative treatment option that enables withdrawal of steroids as well as reduction of CNIs for pediatric kidney transplant recipients. ClinicalTrials.gov: NCT01544491." @default.
• W3024960011 created "2020-05-21" @default.
• W3024960011 creator A5000858931 @default.
• W3024960011 creator A5001765163 @default.
• W3024960011 creator A5006919482 @default.
• W3024960011 creator A5024221918 @default.
• W3024960011 creator A5026720506 @default.
• W3024960011 creator A5032945013 @default.
• W3024960011 creator A5038875933 @default.
• W3024960011 creator A5053507788 @default.
• W3024960011 creator A5060428160 @default.
• W3024960011 creator A5062868134 @default.
• W3024960011 creator A5066781852 @default.
• W3024960011 creator A5069717448 @default.
• W3024960011 creator A5077186881 @default.
• W3024960011 date "2021-01-01" @default.
• W3024960011 modified "2023-10-02" @default.
• W3024960011 title "Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal" @default.
• W3024960011 cites W1500996383 @default.
• W3024960011 cites W1588788406 @default.
• W3024960011 cites W1595026504 @default.
• W3024960011 cites W1600996638 @default.
• W3024960011 cites W1819412255 @default.
• W3024960011 cites W1843997001 @default.
• W3024960011 cites W1892960142 @default.
• W3024960011 cites W1946067182 @default.
• W3024960011 cites W1964959703 @default.
• W3024960011 cites W1981943283 @default.
• W3024960011 cites W1999111416 @default.
• W3024960011 cites W2010330416 @default.
• W3024960011 cites W2010753498 @default.
• W3024960011 cites W2017278250 @default.
• W3024960011 cites W2046773238 @default.
• W3024960011 cites W2055952975 @default.
• W3024960011 cites W2068797950 @default.
• W3024960011 cites W2068820901 @default.
• W3024960011 cites W2075287257 @default.
• W3024960011 cites W2077349622 @default.
• W3024960011 cites W2090563479 @default.
• W3024960011 cites W2120095600 @default.
• W3024960011 cites W2122855609 @default.
• W3024960011 cites W2138695120 @default.
• W3024960011 cites W2168560260 @default.
• W3024960011 cites W2175640221 @default.
• W3024960011 cites W2301879503 @default.
• W3024960011 cites W2312763719 @default.
• W3024960011 cites W2327761020 @default.
• W3024960011 cites W2463501992 @default.
• W3024960011 cites W2535281367 @default.
• W3024960011 cites W2563517383 @default.
• W3024960011 cites W2584967320 @default.
• W3024960011 cites W2734820731 @default.
• W3024960011 cites W2799859234 @default.
• W3024960011 cites W2888436800 @default.
• W3024960011 cites W2915342131 @default.
• W3024960011 cites W2928519391 @default.
• W3024960011 cites W2947554989 @default.
• W3024960011 doi "https://doi.org/10.1111/ajt.16005" @default.
• W3024960011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32406111" @default.
• W3024960011 hasPublicationYear "2021" @default.
• W3024960011 type Work @default.
• W3024960011 sameAs 3024960011 @default.
• W3024960011 citedByCount "10" @default.
• W3024960011 countsByYear W30249600112021 @default.
• W3024960011 countsByYear W30249600112022 @default.
• W3024960011 countsByYear W30249600112023 @default.
• W3024960011 crossrefType "journal-article" @default.
• W3024960011 hasAuthorship W3024960011A5000858931 @default.
• W3024960011 hasAuthorship W3024960011A5001765163 @default.
• W3024960011 hasAuthorship W3024960011A5006919482 @default.
• W3024960011 hasAuthorship W3024960011A5024221918 @default.
• W3024960011 hasAuthorship W3024960011A5026720506 @default.
• W3024960011 hasAuthorship W3024960011A5032945013 @default.
• W3024960011 hasAuthorship W3024960011A5038875933 @default.
• W3024960011 hasAuthorship W3024960011A5053507788 @default.
• W3024960011 hasAuthorship W3024960011A5060428160 @default.
• W3024960011 hasAuthorship W3024960011A5062868134 @default.
• W3024960011 hasAuthorship W3024960011A5066781852 @default.
• W3024960011 hasAuthorship W3024960011A5069717448 @default.
• W3024960011 hasAuthorship W3024960011A5077186881 @default.
• W3024960011 hasBestOaLocation W30249600111 @default.
• W3024960011 hasConcept C120665830 @default.
• W3024960011 hasConcept C121332964 @default.
• W3024960011 hasConcept C126322002 @default.
• W3024960011 hasConcept C126894567 @default.
• W3024960011 hasConcept C141071460 @default.
• W3024960011 hasConcept C159641895 @default.
• W3024960011 hasConcept C168563851 @default.
• W3024960011 hasConcept C197934379 @default.
• W3024960011 hasConcept C2775965419 @default.
• W3024960011 hasConcept C2778715236 @default.
• W3024960011 hasConcept C2779699572 @default.
• W3024960011 hasConcept C2780303639 @default.
• W3024960011 hasConcept C2781413609 @default.
• W3024960011 hasConcept C2909675724 @default.
• W3024960011 hasConcept C2911091166 @default.
• W3024960011 hasConcept C2992435398 @default.
• W3024960011 hasConcept C44249647 @default.

• next